JP2025011259A5 - - Google Patents

Download PDF

Info

Publication number
JP2025011259A5
JP2025011259A5 JP2024180571A JP2024180571A JP2025011259A5 JP 2025011259 A5 JP2025011259 A5 JP 2025011259A5 JP 2024180571 A JP2024180571 A JP 2024180571A JP 2024180571 A JP2024180571 A JP 2024180571A JP 2025011259 A5 JP2025011259 A5 JP 2025011259A5
Authority
JP
Japan
Prior art keywords
ccr9
domain
disease
therapeutic agent
binding molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024180571A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025011259A (ja
Filing date
Publication date
Priority claimed from JP2023556501A external-priority patent/JP7574467B2/ja
Application filed filed Critical
Publication of JP2025011259A publication Critical patent/JP2025011259A/ja
Publication of JP2025011259A5 publication Critical patent/JP2025011259A5/ja
Pending legal-status Critical Current

Links

JP2024180571A 2021-03-18 2024-10-16 治療用結合分子 Pending JP2025011259A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163162603P 2021-03-18 2021-03-18
US63/162,603 2021-03-18
JP2023556501A JP7574467B2 (ja) 2021-03-18 2022-03-17 治療用結合分子
PCT/EP2022/057029 WO2022195028A2 (en) 2021-03-18 2022-03-17 Therapeutic binding molecules

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023556501A Division JP7574467B2 (ja) 2021-03-18 2022-03-17 治療用結合分子

Publications (2)

Publication Number Publication Date
JP2025011259A JP2025011259A (ja) 2025-01-23
JP2025011259A5 true JP2025011259A5 (https=) 2025-03-26

Family

ID=81327268

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023556501A Active JP7574467B2 (ja) 2021-03-18 2022-03-17 治療用結合分子
JP2024180571A Pending JP2025011259A (ja) 2021-03-18 2024-10-16 治療用結合分子

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023556501A Active JP7574467B2 (ja) 2021-03-18 2022-03-17 治療用結合分子

Country Status (19)

Country Link
US (3) US12049506B2 (https=)
EP (2) EP4308607A2 (https=)
JP (2) JP7574467B2 (https=)
KR (2) KR20250069981A (https=)
CN (1) CN116997571A (https=)
AR (1) AR125142A1 (https=)
AU (2) AU2022236492B2 (https=)
CA (1) CA3212630A1 (https=)
CL (1) CL2023002759A1 (https=)
CO (1) CO2023013566A2 (https=)
CR (1) CR20230488A (https=)
EC (1) ECSP23078844A (https=)
IL (2) IL305690B2 (https=)
MA (1) MA71643A (https=)
MX (1) MX2023010917A (https=)
NZ (1) NZ804536A (https=)
TW (1) TWI872319B (https=)
WO (1) WO2022195028A2 (https=)
ZA (1) ZA202309418B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53338A (fr) * 2018-03-05 2022-01-05 Janssen Pharmaceutica Nv Dosages pour détecter la neurodégénérescence
EP4417623A1 (en) * 2023-02-15 2024-08-21 Fundació Institut de Recerca Contra la Leucèmia Josep Carreras Ccr9 targeting moiety for the treatment of ccr9-positive cancer
EP4578874A1 (en) 2023-12-29 2025-07-02 SunRock Biopharma S.L. Anti-ccr9 antibody

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB2183661B (en) 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
WO1990014443A1 (en) 1989-05-16 1990-11-29 Huse William D Co-expression of heteromeric receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6329159B1 (en) * 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
ATE482275T1 (de) 1999-07-02 2010-10-15 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
BR0316101A (pt) 2002-11-07 2005-09-27 Immunogen Inc Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
SG178925A1 (en) 2009-09-22 2012-04-27 Volker Sandig Process for producing molecules containing specialized glycan structures
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
EP2876114A1 (en) * 2013-11-25 2015-05-27 Consejo Superior De Investigaciones Científicas Antibodies against CCR9 and applications thereof
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Similar Documents

Publication Publication Date Title
CN109071664B (zh) 新型抗-SIRPa抗体及其治疗应用
JP2025011259A5 (https=)
JP7397882B2 (ja) 二重特異性抗体及びその調製方法、使用
JP6181043B2 (ja) 抗神経成長因子抗体ならびにそれを調製および使用する方法
JP7355977B2 (ja) Cd24に結合する抗体、その調製および使用
US20120082683A1 (en) Superagonistic Anti-CD28 Antibodies
CN120714023A (zh) 抗pd-1抗体及其用途
WO2007071422A2 (en) Pharmaceutical antibody compositions with resistance to soluble cea
WO2019170898A1 (en) Pd1 binding agents
CN110300764A (zh) 抗SIRPg抗体的新用途
JP2014526902A (ja) イヌ化腫瘍壊死因子抗体及びその使用方法
AU2019349662A1 (en) System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies
WO2023118395A1 (en) Treatment paradigm for an anti-cd19 antibody therapy
PT2171060E (pt) Anticorpo anti-cd28 superagonista
TW202307004A (zh) 抗cea抗體及使用方法
JPWO2022195028A5 (https=)
EP2496257A1 (en) Treatment of cancer involving mutated kras or braf genes
WO2023110937A1 (en) Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
US20230242640A1 (en) ANTI-SIRPg Compounds
US12606617B2 (en) Composition comprising an IgE antibody
RU2833233C2 (ru) Антитела к хелатным радионуклидам
JPWO2023138551A5 (https=)
WO2024044675A1 (en) Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies
TW201321406A (zh) 腫瘤壞死因子抗體及使用其之方法
NZ621619B2 (en) Caninised tumour necrosis factor antibodies and methods of using the same